TNGP Stock Overview
A biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Transgene SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.01 |
| 52 Week High | €0 |
| 52 Week Low | €0 |
| Beta | 0.73 |
| 11 Month Change | 0% |
| 3 Month Change | -12.62% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | -48.26% |
| Change since IPO | -89.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| TNGP | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -4.0% | 0.7% |
| 1Y | n/a | -18.9% | 6.1% |
Return vs Industry: Insufficient data to determine how TNGP performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how TNGP performed against the UK Market.
Price Volatility
| TNGP volatility | |
|---|---|
| TNGP Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: TNGP has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine TNGP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 141 | Alessandro Riva | www.transgene.fr |
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of hepatitis B; TG6050 for the treatment of non-small cell lung cancer, and Pexa-Vec, an oncolytic virus for the treatment of solid tumors.
Transgene SA Fundamentals Summary
| TNGP fundamental statistics | |
|---|---|
| Market cap | €139.91m |
| Earnings (TTM) | -€22.33m |
| Revenue (TTM) | €7.90m |
17.7x
P/S Ratio-6.3x
P/E RatioIs TNGP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TNGP income statement (TTM) | |
|---|---|
| Revenue | €7.90m |
| Cost of Revenue | €29.59m |
| Gross Profit | -€21.69m |
| Other Expenses | €640.00k |
| Earnings | -€22.33m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 24, 2024
| Earnings per share (EPS) | -0.17 |
| Gross Margin | -274.53% |
| Net Profit Margin | -282.63% |
| Debt/Equity Ratio | 102.7% |
How did TNGP perform over the long term?
See historical performance and comparison